Quarterly ResultJul 30, 2026, 07:56 AM
Wave Life Sciences to Redomicile to Delaware; Q2 Net Loss $69.36M
AI Summary
Wave Life Sciences Ltd. reported a net loss of $69.36 million for the second quarter of 2026, with revenue at $2.27 million. For the first six months of 2026, the company's net loss slightly decreased to $95.44 million, while revenue significantly increased to $40.52 million. The company also announced that its redomiciliation to Delaware was approved by shareholders and the High Court of Singapore, expected to take effect in August 2026, and extended its manufacturing facility lease.
Key Highlights
- Shareholders approved the company's redomiciliation to Delaware on June 22, 2026.
- The High Court of Singapore approved the redomiciliation on July 14, 2026, expected in August 2026.
- Net loss for Q2 2026 was $69.36 million, compared to $50.47 million in Q2 2025.
- Revenue for Q2 2026 was $2.27 million, down from $8.70 million in Q2 2025.
- Net loss for H1 2026 was $95.44 million, a slight decrease from $97.35 million in H1 2025.
- Revenue for H1 2026 increased to $40.52 million from $17.87 million in H1 2025.
- Cash, cash equivalents, and marketable securities totaled $490.6 million as of June 30, 2026.
- Extended Lexington, MA manufacturing facility lease through January 2038.
Price Impact
More from WVE